JSAM
STOK icon

J. Safra Asset Management’s Stoke Therapeutics STOK Stock Holding History

J. Safra Asset Management’s Portfolio STOK Stock Details STOK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$9.73K Buy
299
+202
+208% +$6.63K ﹤0.01% 378
2025
Q4 		$3.08K Sell
97
-37
-28% -$1.11K ﹤0.01% 495
2025
Q3 		$3.15K Buy
+134
New +$2.3K ﹤0.01% 347

Other funds holding STOK

RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

J. Safra Asset Management's STOK Position: Q1 2026 in Review

J. Safra Asset Management increased its Stoke Therapeutics (STOK) stake by 208% in Q1 2026, buying an estimated $6.63K and bringing the position to 299 shares worth $9.73K. The position accounts for ﹤0.01% of the portfolio, ranked #378.

J. Safra Asset Management first reported a position in STOK in Q3 2025 and has held it in 3 quarters since. 196 funds tracked by Wall St. Rank hold STOK as of Q1 2026.

  • J. Safra Asset Management held 299 shares of Stoke Therapeutics worth $9.73K as of Q1 2026.
  • J. Safra Asset Management bought 202 Stoke Therapeutics shares in Q1 2026, an estimated $6.63K.
  • Stoke Therapeutics made up ﹤0.01% of J. Safra Asset Management's portfolio in Q1 2026, its #378 holding.
  • J. Safra Asset Management first reported a position in Stoke Therapeutics in Q3 2025 and has held it in 3 quarters since.
  • 196 funds tracked by Wall St. Rank held Stoke Therapeutics as of Q1 2026.

Based on J. Safra Asset Management's 13F filing for Q1 2026, filed 4 May 2026.